Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.

Expert review of hematology - 1 May 2016

Jamil Muhammad O, Mehta Amitkumar

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma (NHL). DLBCL is clinically, pathologically and molecularly heterogeneous disease. Various clinical, pathological and molecular markers have been developed to characterize the disease. Based on these characterizations, new targeted agents are being investigated to optimize the treatment and improve the outcomes of DLBCL. Enhanced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunohistochemistry

Share to Lymphoma, Large B-Cell, Diffuse

Share to Molecular Targeted Therapy

Share to Positron-Emission Tomography

Share to Tumor Microenvironment

Source

Identifiers

PMID: 26808217
DOI: 10.1586/17474086.2016.1146584

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy.PMID 26808217Read ↗

Next-generation prognostic assessment for diffuse large B-cell lymphoma.Semantic proximity Read ↗

Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapySemantic proximity Read ↗

Molecular pathogenesis of diffuse large B-cell lymphoma.Semantic proximity Read ↗

Novel therapeutic targets in diffuse large B-cell lymphomaSemantic proximity Read ↗

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment.Semantic proximity Read ↗

Diffuse large B-cell lymphoma.Semantic proximity Read ↗

Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.Semantic proximity Read ↗

Classifying DLBCL Subtypes for Optimal Treatment.Semantic proximity Read ↗

Are We Ready To Stratify Treatment for Diffuse Large B-Cell Lymphoma Using Molecular Hallmarks?Semantic proximity Read ↗

Prognostic values of various clinical factors and genetic subtypes for diffuse large B-cell lymphoma patients: a retrospective analysis of 227 cases.Semantic proximity Read ↗

Predictive and prognostic molecular biomarkers in lymphomas.Semantic proximity Read ↗

Clinicopathological features and prognostic factors of rare primary bone marrow diffuse large B cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.